Animal studies have shown that a new treatment strategy using phototherapy might be used to treat inaccessible cancers, including multiple…
Iqra Mumal, MSc
Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Iqra Mumal, MSc
MYELOMA
CAR T-cells Targeting Integrin β7 Protein Show Promise in Countering Multiple Myeloma Cells
A Japanese study has found that an active structure of the protein integrin β7 is specific to multiple myeloma cells,…
The developers of the myeloma therapy candidate bb2121 have started an extension study of a Phase 1 clinical trial to…
Stem cell transplants derived from patients’ own bone marrow are a safe and effective treatment for those with multiple myeloma who…
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and…
MYELOMA
Potential Use of Ninlaro as Maintenance Therapy in Multiple Myeloma Shown in Phase 1/2 Trials
Patients with newly diagnosed multiple myeloma benefit significantly from a combination of Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone, followed…